Review
doi: 10.3322/canjclin.43.3.177.
Immunotherapy of renal cell carcinoma
Affiliations
- PMID: 8490757
- DOI: 10.3322/canjclin.43.3.177
Item in Clipboard
Review
Immunotherapy of renal cell carcinoma
CA Cancer J Clin.
1993 May-Jun.
Free article
Abstract
Immunologic approaches to the therapy of metastatic renal cell carcinoma have provided moderate improvement in response rates for a disease that is extremely resistant to all forms of treatment. This article reviews recent clinical efforts using immunotherapy for renal cell carcinoma, including the adoptive transfer of cytotoxic killer cells and/or the use of biologic response modifiers, such as interferon and interleukin-2.
Similar articles
-
Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.Semin Oncol. 1993 Dec;20(6 Suppl 9):11-5. Semin Oncol. 1993. PMID: 8284686 Review. No abstract available.
-
Cancer immunotherapy using tumor-infiltrating lymphocytes.Semin Hematol. 1992 Apr;29(2 Suppl 1):33-5. Semin Hematol. 1992. PMID: 1535456 Clinical Trial. No abstract available.
-
Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.J Clin Oncol. 1995 Aug;13(8):1939-49. doi: 10.1200/JCO.1995.13.8.1939. J Clin Oncol. 1995. PMID: 7636534 Clinical Trial.
-
Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma.J Urol. 1993 Nov;150(5 Pt 1):1384-90. doi: 10.1016/s0022-5347(17)35785-3. J Urol. 1993. PMID: 8411405 Clinical Trial.
-
Adoptive cellular therapy.Semin Oncol. 2000 Apr;27(2):221-33. Semin Oncol. 2000. PMID: 10768601 Review.
Cited by
-
Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma.Br J Cancer. 2005 Oct 3;93(7):757-62. doi: 10.1038/sj.bjc.6602768. Br J Cancer. 2005. PMID: 16136045 Free PMC article. Clinical Trial.
-
Growth and major histocompatibility antigen expression regulation by IL-4, interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) on human renal cell carcinoma.Clin Exp Immunol. 1994 Jun;96(3):476-83. doi: 10.1111/j.1365-2249.1994.tb06054.x. Clin Exp Immunol. 1994. PMID: 8004818 Free PMC article.
-
In vivo assessment of the antiproliferative properties of interferon-alpha during immunotherapy: Ki-67 (MIB-1) in patients with metastatic renal cell carcinoma.Br J Cancer. 2004 Feb 9;90(3):626-31. doi: 10.1038/sj.bjc.6601587. Br J Cancer. 2004. PMID: 14760375 Free PMC article. Clinical Trial.
-
Treatment of metastatic renal cell carcinoma.Nat Rev Urol. 2010 Jun;7(6):327-38. doi: 10.1038/nrurol.2010.57. Epub 2010 May 11. Nat Rev Urol. 2010. PMID: 20458330 Review.
-
L- and M2-pyruvate kinase expression in renal cell carcinomas and their metastases.Virchows Arch. 1994;424(2):177-85. doi: 10.1007/BF00193498. Virchows Arch. 1994. PMID: 8180780
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
